echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Cancer cell: develop a new method to effectively block the metastasis of melanoma

    Cancer cell: develop a new method to effectively block the metastasis of melanoma

    • Last Update: 2020-02-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 13, 2020 / BIOON / -- recently, in a research report published in the international journal Cancer Cell, scientists from the University of Valencia and other institutions developed a new method to effectively block the occurrence and metastasis of melanoma through research; in the article, researchers found a special genetic Substance, which may prevent cancer cells on the skin from moving in the distance to form metastasis, so researchers are expected to study new cancer biomarkers to help develop new anti-cancer therapies Image source: asocici ó n ruvid In this study, the researchers surrounded circular RNA RNA) to carry out research, because most RNAs are linear molecules, and only a part of them are circular molecules, unlike most RNA molecules, circular RNA does not produce proteins, which is part of the complex regulatory system of cells At present, researchers do not know its specific functions; after researchers conducted research on cell cultures, for the first time, they found that they are missing Circrna, called cdr1as, may be beneficial for tissue invasion and melanoma metastasis; in fact, after studying human tissues, researchers found that a lower level of cdr1as was directly related to a shorter survival time of patients Melanoma is a kind of malignant skin cancer, and it is also a very meaningful model to investigate cancer metastasis The main cause of death of melanoma patients is the spread and metastasis of cancer cells, which may be directly related to the existence of cdr1as The significance of this study is twofold It not only reveals the functional, prognostic and predictive role of cdr1as in melanoma patients, but also reveals that circular RNAs may be the key molecule to promote the occurrence and metastasis of cancer Based on this, the researchers have revealed the malignant behavior of melanoma and given the evidence for the first time that circular RNAs may play a role The inhibitory molecules of melanoma metastasis According to the researchers, cdr1as can slow down the function of cancer promoting protein IGF2BP3, which is also of great significance to the treatment of clinical patients At present, researchers still urgently need to conduct research on a large number of cancer patients to identify patients with high risk of cancer metastasis In addition, for patients with advanced stage, having biomarkers that can predict the response to treatment may be helpful for Choosing the most appropriate, effective and personalized treatment is of great help; in this sense, the level of cdr1as may be a very valuable biomarker, which can be widely used in the treatment of melanoma and other types of tumors Original source: Douglas hanniford, Alejandro Ulloa Morales, alcida karz, et al Epigenetic silencing of cdr1as drives IGF2BP3 mediated melanioma innovation and metastasis, cancer cell (2020) Doi: 10.1016/j.ccell.2019.12.007
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.